Full Fed. Circ. Won't Revive Juno's $1.2B Cancer Patent Win
The full Federal Circuit said Friday that it will not review a panel decision wiping out Bristol-Myers Squibb subsidiary Juno Therapeutics' $1.2 billion patent infringement victory against Gilead's Kite Pharma Inc....To view the full article, register now.
Already a subscriber? Click here to view full article